X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-cap-out-of-pocket-inhaler-costs-us-2024-03-20/
https://endpts.com/drugmakers-benefit-substantially-from-secondary-patents-on-inhalers-report/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-27-2021-1635324993.pdf
https://www.bloomberg.com/press-releases/2020-09-21/teva-launches-two-digital-inhalers-in-the-u-s-airduo-digihaler-fluticasone-propionate-and-salmeterol-inhalation-powder
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-submits-application-with-usfda-for-generic-version-of-asthma-drug/articleshow/75798947.cms
https://www.moneycontrol.com/news/business/markets/cipla-share-price-up-8-on-successful-completion-of-phase-3-clinical-study-of-asthma-drug-5104691.html
https://njbiz.com/teva-announces-fda-approval-armonair-digihaler-inhalation-powder/
https://www.fiercepharma.com/pharma/gsk-leaning-respiratory-franchise-shingrix-as-advair-generics-march
https://www.biopharmadive.com/news/astrazeneca-pt010-fda-rejection-copd-gsk-respiratory-competition/564090/
https://endpts.com/charging-at-blockbuster-advair-novartis-boasts-topline-victories-for-asthma-drugs-in-twin-phiii-studies/
https://www.raps.org/news-and-articles/news-articles/2019/9/product-hopping-ec-hearing-addresses-restriction
https://www.fiercepharma.com/pharma/gsk-holds-firm-despite-advair-generics-thanks-to-new-respiratory-drugs-and-shingrix
https://www.fiercepharma.com/pharma/astrazeneca-s-copd-triplet-breztri-rival-to-gsk-s-trelegy-nabs-first-nod-from-japan
https://www.reuters.com/article/us-gsk-pharmaceuticals/gsk-pharma-head-flags-need-for-speed-in-high-pressure-drug-market-idUSKCN1TI1TT
https://www.fiercebiotech.com/biotech/novartis-asthma-triplet-beats-gsk-s-advair-phase-2-trial
https://www.fiercepharma.com/pharma/mylan-investors-have-had-it-management-analysts-say
https://www.biopharmadive.com/news/generic-advair-hits-gsk-revenues-hard/553868/
https://www.biopharmadive.com/news/mylan-advair-generic-gsk-strong-launch/550093/
https://www.cnbc.com/2019/03/07/biotech-shares-continue-to-fall-on-fda-uncertainty.html
https://www.cnbc.com/2019/02/27/reuters-america-mylan-shares-sink-as-bleak-profit-outlook-sparks-growth-concerns.html
https://www.proactiveinvestors.co.uk/companies/news/215126/ubs-strips-gsk-of-buy-recommendation-on-near-term-fears-for-its-viiv-hiv-division-215126.html
https://www.fiercepharma.com/pharma/mylan-s-aggressive-generic-advair-discount-isn-t-as-big-as-it-looks-analysts
https://www.medtechdive.com/news/fda-draft-lays-out-submission-paths-for-combo-products/547807/
https://endpts.com/hal-barrons-gsk-team-continues-to-cull-respiratory-drugs-in-big-shift-to-oncology-rd/
https://www.raps.org/news-and-articles/news-articles/2019/1/mylan-wins-fda-approval-for-first-advair-generic
https://endpts.com/after-a-years-long-reprieve-gsk-is-about-to-see-mylans-generic-carve-into-its-mega-blockbuster-advair-franchise/
https://endpts.com/vectura-sinks-after-phiii-asthma-trial-ends-in-failure-marking-another-setback/
https://www.fiercepharma.com/pharma/generic-advair-you-expect-it-will-come-but-let-s-look-at-other-products-says-mylan
https://www.bloombergquint.com/onweb/mylan-s-beat-lifts-hopes-that-worst-is-over-for-generic-makers
https://www.fiercepharma.com/manufacturing/glaxosmithkline-opens-expanded-api-production-for-copd-inhalers
https://www.fiercepharma.com/pharma/mylan-reveals-its-mystery-buy-and-it-s-novartis-tobi-cystic-fibrosis-products
http://www.pmlive.com/pharma_news/az_rival_to_gsks_copd_drug_anoro_fails_head-to-head_test_1249945
https://endpts.com/hit-by-surprise-setback-astrazeneca-scrambles-to-explain-why-its-two-in-one-copd-inhaler-fails-to-beat-gsk-rival/
https://endpts.com/gsk-chief-emma-walmsley-rounds-out-her-top-team-with-cfo-pick-but-performance-lags/
https://www.nasdaq.com/article/whats-in-the-cards-for-glaxo-gsk-this-earnings-season-cm995190
https://in.reuters.com/article/us-mylan-advair/fda-finds-deficiencies-in-mylans-generic-advair-shares-fall-idINKBN1J931R
https://www.cnbc.com/2018/06/13/reuters-america-update-2-fda-finds-deficiencies-in-mylans-generic-advair-shares-fall.html
https://www.fiercepharma.com/pharma/mylan-ceo-bresch-epipen-scandal-was-opportunity-to-discuss-flawed-pricing-system
https://www.bloomberg.com/news/articles/2018-05-04/glaxo-s-advair-is-the-100-billion-asthma-drug-that-won-t-die
https://www.fiercepharma.com/marketing/glaxosmithkline-pharma-boss-miels-streamlines-commercial-ops-to-highlight-trelegy
https://www.fiercepharma.com/pharma/hikma-cues-200-more-layoffs-as-generics-manufacturing-distribution-consolidation-continues
https://www.fiercepharma.com/pharma/fda-sends-hikma-vectura-back-to-clinic-advair-copy-now-due-2020?mkt_tok=eyJpIjoiWXpreE9EZG1ZVFUxWm1VMiIsInQiOiJqTmczRU9rQ3luRVhkbjc4YzRMMW1Ndk01ZitVWjlWTDloSWEreXo1YnVUOVZNM1haZDlNMlV3eU1IYk90K0dcL3hFVUVJSHV0R0hsUm9FTU8yRkFIRHZhZk1adTBIc3B3OVwvWENjXC9YNFVNSmZDM3Z5cmhhTTJ5cW0rUGRBZmExRSJ9&mrkid=16780123
https://www.reuters.com/article/us-hikma-gsk-advair/gsk-escapes-advair-hit-for-now-as-second-generic-bid-fails-idUSKBN1870OP
https://www.fiercepharma.com/pharma/bad-news-for-novartis-good-for-glaxo-sandoz-advair-copy-stiff-armed-at-fda
https://www.reuters.com/article/us-gsk-results/glaxosmithkline-sees-light-at-end-of-advair-tunnel-idUSKBN1FR1PW?feedType=RSS&feedName=healthNews
http://www.fiercepharma.com/pharma/decade-s-top-10-patent-losses-featuring-seismic-sales-shifts
http://sharecast.com/news/hikma-pharma-trims-guidance-as-generic-advair-talks-continue-with-fda/26325812.html
http://www.fiercepharma.com/pharma/mylan-points-finger-at-fda-for-failure-to-win-nods-advair-copaxone-copies
Market Place
Share 
